If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||
![]() Clinical GeneticsVolume 69 Issue 4, Pages 344 - 348 Published Online: 30 Mar 2006 © 2010 John Wiley & Sons A/S
Abstract | References | Full Text: HTML, PDF (Size: 103K) | Related Articles | Citation Tracking Short Report A successful approach for the detection of Fabry patients in Argentina Copyright Blackwell Munksgaard, 2006 KEYWORDS alpha galactosidase • diagnosis • Fabry disease • lysosomal storage disorder Rozenfeld PA, Tarabuso A, Ebner R, Ramallo G, Fossati CA. A successful approach for the detection of Fabry patients in Argentina. ABSTRACTFabry disease is an X-linked lysosomal disorder caused by the deficiency of the lysosomal enzyme α-galactosidase A (α-Gal A). In males, the laboratory diagnosis is based on the demonstration of decreased levels of α-Gal A activity, while in females, the disease is diagnosed by the identification of a mutation in α-Gal A gene. Fabry disease in Argentina is underdiagnosed. To date, no comprehensive screening study of Fabry disease in our country has been reported. The present study aimed at developing a targeted screening for the detection of Fabry patients from Argentina based on the set of typical signs and symptoms. We received 121 blood samples from probable Fabry patients for enzymatic and genetic assay. We diagnosed six Fabry patients from six unrelated families, representing a yield of detection of 4.96%. The mutations detected in five of the families analysed were missense mutations: p.Leu243Trp, p.Asp155His, p.Leu415Pro, p.Cys94Tyr and p.Leu191Pro. After the detection of a Fabry patient, his/her relatives were also screened. In the course of these family studies, other 64 Fabry patients, 29 males and 35 females, were detected. To our knowledge, this is the first comprehensive screening of Fabry disease in Argentina. We detected 70 patients in a period of 2.5 years. The development of targeted protocols and the constitution of interdisciplinary groups for the identification of patients with Fabry disease are recommended to obtain a higher yield in the process. Received 4 November 2005, revised and accepted for publication 25 January 2006 |